For instance, EZH2- and PKM2-mediated co-silencing of SLC16A9 in triple-negative breast cancer (TNBC) induces a metabolic shift from glycolysis to fatty acid oxidation, highlighting potential for synthetic lethality via dual-targeting strategies (114). The gene discussed is SLC16A9; the disease is triple-negative breast carcinoma.